Xellia Pharmaceuticals ApS

Ledelsesberetning

Statutory statement regarding data ethics in accordance with section 99d of the Danish Financial Statements Act

Beskrivelse af virksomhedens væsentligste aktiviteter

Business review
Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing, and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.
Xellia is a global leader in providing anti-infective treatments for serious and often life-threatening conditions. Xellia has an extensive history in developing, manufacturing, and commercializing anti-infective products, including Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF). As an organization, Xellia is committed to providing security and consistency in the supply of critical care therapies. Through a global interlocked supply chain, the company continuously works to improve supply security through multiple sources of in-house production of its APIs and drug products and working alongside Xellia’s R&D center. Supplying products to more than 80 countries worldwide and with more than 500 customers internationally, Xellia is the leading supplier of several essential anti-infectives, including vancomycin, tobramycin, amphotericin, and colistimethate sodium (CMS).
Headquartered in Copenhagen, Denmark, Xellia has a global footprint with manufacturing, R&D, and commercial operations across Europe, Asia, the Middle East, and North America. Xellia’s three manufacturing facilities, located in China, Denmark, and Hungary, operate according to current Good Manufacturing Practice (cGMP), and Xellia’s facilities have been inspected by relevant regulatory health authorities.
Xellia is a Business-to-business company that provides APIs to pharmaceutical companies worldwide. The B2B business is supported by the quality assurance, supply and distribution, and R&D teams. The Global sales organization operates in all geographic markets and oversees the three plants in Denmark, Hungary, and China. In addition to supporting current customers, the sales organization continuously works to introduce the company’s core product portfolio to new markets.
Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,200 full-time employees.
Further information about Xellia can be found at:
www.xellia.com

Beskrivelse af usikkerhed ved indregning eller måling

Recognition and measurement uncertainties
The recognition and measurement of items in the Annual Report is not subject to material uncertainties that could significantly impact the Annual Report.

Beskrivelse af udviklingen i virksomhedens aktiviteter og økonomiske forhold

Financial review
The company's income statement for the year ended December 31, 2024, shows a net profit of MDKK 828,9 and the balance sheet on December 31, 2024, shows an equity of MDKK 162,5.
Investments
In 2024, Xellia invested MDKK 0,3 in intangible assets and MDKK 42,2 in tangible assets to maintain and upgrade current production facilities and to meet compliance requirements.

Omtale af betydningsfulde hændelser, som er indtruffet efter regnskabsårets afslutning

Uncertainties relating to going concern
The parent company New Xellia Group A/S has issued a Letter of support to which the parent company will provide any support necessary for Xellia Pharmaceuticals ApS to fulfil its obligations until January 1, 2026.
Based on the circumstances described above, the financial statements are prepared by the Management on the basis that Xellia Pharmaceuticals ApS is a going concern.

Beskrivelse af virksomhedens forventede udvikling

Subsequent events
After the balance sheet date, the following significant subsequent event occurred in the period between the end of the financial year and the Board of Directors’ adoption of the annual report.
The parent company New Xellia Group A/S held a Board of Directors meeting on 18 February 2025, and budget and plans for gradual closure of the production site in Copenhagen over a ten-year period was approved. The detailed planning and design of this is an ongoing process that is affected by capital and operating expenditures as well as geopolitical factors.
No further events after the balance sheet date have occurred which could significantly have affected the company’s financial position.